Advaxis ADXS Stock News

Dynavax Technologies Corporation (NASDAQ: DVAX) is rocketing early this morning, trading on gains of more than 40%. The gains come after an SEC filing was made public, suggesting that the company’s COVID-19 vaccine will be headed into human trials. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

DVAX Stock Heads Up On SEC Filing Surrounding COVID-19

In the SEC filing, Dynavax said that it would provide an update on early-stage collaborations surrounding its development of a COVID-19 vaccine today in a meeting with securities analysts and investors.

The company’s vaccine candidate contains its toll-like receptor 9 agonist adjuvant, known as CpG-1018. This is the same adjuvant used in the company’s HEPLISAV-B product.

The most important quote from DVAX in the filing is as follows:

“The update is that the Company expects that one or more of its collaboration partners will commence a Phase 1 clinical trial of a potential COVID-19 vaccine as soon as July 2020.”

That’s right. In the SEC filing, Dynavax said that it expects for one or more of its partners to move forward with a Phase 1 clinical trial in the very near term.

This News Is Huge!

For DVAX, the news issued today is overwhelmingly positive. The truth of the matter is that while states are beginning to repopen their economies, the COVID-19 pandemic is still far from over. In order to put an end to it, we need to have vaccines available on a massive scale.

Sure, there are several companies that are working on vaccines. However, very few of these companies actually have anything of substance. Many of those with something of substance simply aren’t ready for the clinic.

With the news in the SEC filing, we see that DVAX has a vaccine that is clinic ready. Just as importantly, it looks like the company’s partners will be pushing it into the clinic very soon.

Even if Dynavax isn’t the first to produce a COVID-19 vaccine, the potential here is incredible. Think about it, when vaccines start to become available, the target market is everyone. The entire global population.

No single company is going to be able to produce enough of the vaccine to meet demand. So, as long as the production of the vaccine is timely, the potential revenue growth that we could see out of this product is incredible. All in all, there’s good reason that investors are excited about DVAX stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts.

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.